Advertisement
Advertisement
SGMT
Sagimet Biosciences Inc. Series A Common Stock
9.24
USDSponsored
+0.13
+1.43%
Sep 25, 15:59 UTC -4
Closed
After-Market
9.21
-0.04
-0.38%
SGMT Earnings Reports
Positive Surprise Ratio
SGMT beat 8 of 13 last estimates.
62%
Next Report
Date of Next Report
Nov 16, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.26
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-35.00%
Sagimet Biosciences Inc. Series A Common Stock earnings per share and revenue
On Aug 11, 2026, SGMT reported earnings of -0.26 USD per share (EPS) for Q2 26, missing the estimate of -0.25 USD, resulting in a -3.54% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.26 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Sagimet Biosciences Inc. Series A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.26, missing estimates by -3.54%, and revenue of $0.00, 0% as expectations.
How did the market react to Sagimet Biosciences Inc. Series A Common Stock's Q2 2026 earnings?
The stock price moved -- 0%, changed from $10.58 before the earnings release to $10.58 the day after.
When is Sagimet Biosciences Inc. Series A Common Stock expected to report next?
The next earning report is scheduled for Nov 16, 2026.
What are the forecasts for Sagimet Biosciences Inc. Series A Common Stock's next earnings report?
Based on 7
analysts, Sagimet Biosciences Inc. Series A Common Stock is expected to report EPS of -$0.26 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.